Page last updated: 2024-11-08

cp 100356

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CP 100356: modulates multidrug resistance; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID196918
CHEMBL ID2075048
SCHEMBL ID6053558
MeSH IDM0230920

Synonyms (12)

Synonym
cp-100356
cp 100356
4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine
CHEMBL2075048
cp100356
2-quinazolinamine, 4-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)-n-(2-(3,4-dimethoxyphenyl)ethyl)-6,7-dimethoxy-
142716-85-6
SCHEMBL6053558
4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)-n-(3,4-dimethoxyphenethyl)-6,7-dimethoxyquinazolin-2-amine
DTXSID20162139
4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine
G7R ,

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Intestinal P-gp and CYP3A4 work coordinately to reduce the intracellular concentration of drugs, and drug-drug interactions (DDIs) based on this interplay are of clinical importance and require pre-clinical investigation."( The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
de Graaf, IA; de Jager, MH; Groothuis, GM; Li, M; van de Steeg, E, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID681357TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in Caco-2 cells1999Cancer research, Aug-15, Volume: 59, Issue:16
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (37.50)18.2507
2000's2 (25.00)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]